Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.

Repeated serosurveys are an important tool for understanding trends in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination. During 1 September 2020-20 March 2021, the NYC Health Department conducted a population-based SARS-CoV-2 antibody prevalence survey of 2096 NYC adults who either provided a blood specimen or self-reported the results of a previous antibody test. The serosurvey, the second in a series of surveys conducted by the NYC Health Department, aimed to estimate SARS-CoV-2 antibody prevalence across the city and for different groups at higher risk for adverse health outcomes. Weighted citywide prevalence was 23.5% overall (95% confidence interval (CI) 20.1-27.4) and increased from 19.2% (95% CI 14.7-24.6) before coronavirus disease 2019 vaccines were available to 31.3% (95% CI 24.5-39.0) during the early phases of vaccine roll-out. We found no differences in antibody prevalence by age, race/ethnicity, borough, education, marital status, sex, health insurance coverage, self-reported general health or neighbourhood poverty. These results show an overall increase in population-level seropositivity in NYC following the introduction of SARS-CoV-2 vaccines and highlight the importance of repeated serosurveys in understanding the pandemic's progression.

Usability Testing of a mHealth App to Support Self-Management of HIV-Associated Non-AIDS Related Symptoms.

Mobile health (mHealth) applications (apps) are uniquely poised to offer the information that persons living with HIV (PLWH) need to manage the symptoms associated with their chronic condition. The purpose of this study was to assess the usability of a mHealth app designed to help PLWH self-man-age the symptoms associated with their HIV and HIV-associated non-AIDS (HANA) conditions. We conducted a heuristic evaluation with five experts in informatics and end-user testing with 20 PLWH. End-users completed the PSSUQ and Health-ITUES validated measures of system usability. Mean severity scores for the 10-item heuristic checklist com-pleted by experts ranged from 0.4-2.4. End-users gave the system high scores on the PSSUQ and Health-ITUES usability measures (mean 2.23 ± 0.83 and 4.24 ± 0.62 respectively). Results indicated the system is usable and will be ready for future efficacy testing after incorporation of recommended feedback.